Natco Pharma increases equity stake in Adcock Ingram to 49% via ₹10.69 billion investment

Natco Pharma's board has approved a ₹10.69 billion investment to increase its equity stake in Adcock Ingram from 35.75% to 49%. This strategic acquisition will allow the Indian generic drugmaker to consolidate its share of the subsidiary's profits and strengthen its international pharmaceutical manufacturing footprint.

According to official disclosures, the board of Natco Pharma, an Indian pharmaceutical company specializing in generic formulations, has authorized the acquisition of additional shares in Adcock Ingram, a prominent therapeutic medicines manufacturer. The ₹10.69 billion transaction will elevate Natco's equity holding in the target entity from 35.75% to 49%, pending standard regulatory approvals.

This capital deployment is strategically significant as it transitions the investment from a minority associate to a near-majority holding, fundamentally altering the financial consolidation dynamics. By securing a 49% stake, Natco Pharma will now recognize nearly half of Adcock Ingram's post-tax profits directly on its consolidated balance sheet.

The move directly impacts the cross-border generic pharmaceutical sector, specifically strengthening supply chain integration and market access in the target's regional operating landscape. Adcock Ingram recently reported robust financial health, generating US$423 million in revenue and approximately US$59 million in EBITDA over the nine months ending March 2026.

For investors and market analysts, this consolidation signals a broader trend of emerging-market pharmaceutical firms optimizing their international joint ventures. The enhanced profit-sharing mechanism is expected to improve Natco's overall earnings visibility and cash flow generation, providing a more resilient financial buffer against domestic pricing pressures.